Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVI-VZV-001 Vaccine in Healthy Adults Aged 50 to 64 Years
NCT06137755Phase 1Completed
- Sponsor
- AriBio Lab
- Start
- Mar 2023
- Primary completion
- Jan 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of CVI-VZV-001 in herpes zoster (HZ) (4 arms), sponsored by AriBio Lab. Primary endpoints: Immediate adverse events, Solicited local and systemic signs and symptoms and 5 more. Started Mar 2023; status: completed.
02
Drugs
CVI-VZV-001
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT06137755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06137755.